GMT Capital’s Aclaris Therapeutics ACRS Stock Holding History

GMT Capital’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-55,300	Closed	-$1.1M	–	104
2018 Q2	$1.1M	Buy	+55,300	New	+$1.02M	0.03%	99

Other funds holding ACRS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GMT Capital's ACRS Position: Q3 2018 in Review

GMT Capital sold out of Aclaris Therapeutics (ACRS) in Q3 2018, closing a stake of 55,300 shares — an estimated $1.1M sold.

GMT Capital first reported a position in ACRS in Q2 2018 and held it in 1 quarter. The position peaked at $1.1M in Q2 2018. 86 funds tracked by Wall St. Rank hold ACRS as of Q3 2018.

GMT Capital reported no remaining Aclaris Therapeutics position as of Q3 2018 after selling out during the quarter.
GMT Capital sold 55,300 Aclaris Therapeutics shares in Q3 2018, an estimated $1.1M.
GMT Capital first reported a position in Aclaris Therapeutics in Q2 2018 and held it in 1 quarter.
GMT Capital's Aclaris Therapeutics position peaked at $1.1M in Q2 2018.
86 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2018.

Based on GMT Capital's 13F filing for Q3 2018, filed 14 Nov 2018.